Lansoprazol Teva-Ratiopharm

Lansoprazole, the active ingredient in Lansoprazol Teva‑Ratiopharm, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat acid‑related disorders such as GERD, peptic ulcer disease and erosive esophagitis in adults.

GNH USA supplies Lansoprazol Teva‑Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor indicated for several acid‑related conditions: - Gastroesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation. - Peptic ulcer disease: promotes healing of gastric and duodenal ulcers. - Erosive esophagitis: reduces mucosal damage caused by acid reflux. - Helicobacter pylori eradication (in combination): enhances antibiotic effectiveness in eradication regimens.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, usually self‑limiting. - Nausea: occasional upset stomach. - Abdominal pain: cramping or discomfort. - Flatulence: increased gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent diarrhea, abdominal pain. - Low magnesium levels: muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: abnormal liver function tests. - Acute interstitial nephritis: kidney inflammation, reduced urine output.

Before using Lansoprazol Teva‑Ratiopharm, consider the following safety measures: - Assess renal function: adjust use in severe kidney impairment. - Review hepatic status: monitor liver enzymes in patients with liver disease. - Evaluate long‑term therapy: consider bone health and magnesium monitoring. - Avoid abrupt discontinuation: taper to prevent rebound acid hypersecretion. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lansoprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption, loss of efficacy. - Antifungal agents (e.g., itraconazole, ketoconazole): markedly decreased bioavailability. - Clopidogrel: diminished antiplatelet effect, increased cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation. - Methotrexate (high dose): possible accumulation, watch for toxicity. - Digoxin: slight increase in serum levels, assess for signs of toxicity. - Diazepam: modest rise in plasma concentration, monitor sedation.